Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines

Daewoong Pharmaceutical

Status and phase: Completed; Phase 1

Conditions: Glabellar Lines

Treatments: Biological: BOTOX®; Biological: DWP712

Study type: Interventional

Funder types: Industry

Identifiers

NCT06212960

DW_DWP712101

Details and patient eligibility

About

To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.

Enrollment: 20 patients

Sex: All

Ages: 19 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subjects with facial wrinkle scale (FWS) score of visual appearance of glabellar lines ≥2 (moderate) at maximum frown as assessed by the investigator at screening

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

20 participants in 2 patient groups

DWP712

Experimental group

Description:

Patients were intramuscularly injected (IM) with a total of 20U of DWP712 in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.

Treatment:

Biological: DWP712

Botox®

Active Comparator group

Description:

Patients were intramuscularly injected (IM) with a total of 20U of BOTOX® in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.

Treatment:

Biological: BOTOX®